Assembly Bill A7645

2009-2010 Legislative Session

Eliminates prior authorization under the preferred drug program for medications indicated by the Food and Drug Administration for the treatment of asthma

download bill text pdf

Sponsored By

Archive: Last Bill Status - In Assembly Committee

  • Introduced
    • In Committee Assembly
    • In Committee Senate
    • On Floor Calendar Assembly
    • On Floor Calendar Senate
    • Passed Assembly
    • Passed Senate
  • Delivered to Governor
  • Signed By Governor

Do you support this bill?

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.
Actions

2009-A7645 (ACTIVE) - Details

Current Committee:
Assembly Health
Law Section:
Public Health Law
Laws Affected:
Amd ยงยง272 & 274, Pub Health L
Versions Introduced in 2011-2012 Legislative Session:
A3573

2009-A7645 (ACTIVE) - Summary

Provides that there shall be no prior authorization required under the preferred drug program for all medications indicated by the federal Food and Drug Administration for the treatment of asthma.

2009-A7645 (ACTIVE) - Bill Text download pdf 

                            
                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  7645

                       2009-2010 Regular Sessions

                          I N  A S S E M B L Y

                             April 17, 2009
                               ___________

Introduced  by  M.  of  A. P. RIVERA, POWELL, PERALTA, RAMOS, ESPAILLAT,
  N. RIVERA, J. RIVERA, DIAZ, V. LOPEZ, ARROYO -- Multi-Sponsored by  --
  M.  of  A. ALFANO, BARRA -- read once and referred to the Committee on
  Health

AN ACT to amend the public health law, in relation to providing that  no
  prior authorization shall be required under the preferred drug program
  for  all medications indicated by the Food and Drug Administration for
  the treatment of asthma

  THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section  1. Subdivision 12 of section 272 of the public health law, as
added by section 10 of part C of chapter 58 of  the  laws  of  2005,  is
amended to read as follows:
  12.  No prior authorization shall be required under the preferred drug
program for: (a) atypical  anti-psychotics;  (b)  anti-depressants;  (c)
anti-retrovirals  used  in the treatment of HIV/AIDS; [and] (d) anti-re-
jection drugs used for the treatment of organ  and  tissue  transplants;
(e)  any  other therapeutic class for the treatment of mental illness or
HIV/AIDS, recommended by the committee and approved by the  commissioner
under  this  section;  AND  (F) ALL MEDICATIONS INDICATED BY THE FEDERAL
FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF ASTHMA.
  S 2. Paragraphs (b) and (c) of subdivision 3 of  section  274  of  the
public health law, as added by section 10 of part C of chapter 58 of the
laws  of  2005,  are amended and a new paragraph (d) is added to read as
follows:
  (b) the potential for, or a history of, overuse, abuse, drug diversion
or illegal utilization; [and]
  (c) the potential for, or a history of, utilization inconsistent  with
approved  indications. Where the commissioner finds that a drug meets at
least one of these criteria, in determining whether  to  make  the  drug
subject  to  prior authorization under the clinical drug review program,

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.
                                                           LBD10778-01-9

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.